Corona Remedies IPO Review 2025 — Price Band, GMP, Allotment & Recommendation
Corona Remedies IPO – Price Band, GMP Trend, Subscription, Allotment, RHP/DRHP & Detailed Review (2025)
Prepared by Money Bells Global Research Services Pvt. Ltd. (SEBI Registered Research Analyst – INH100009901)
📩 Get Premium IPO & Equity Research Reports
Create your Moneybells account and get instant access to research reports directly in your dashboard.
👉 Sign Up & Access Reports📘 Table of Contents
1. Corona Remedies IPO – Summary
Corona Remedies Limited is a fast-growing Indian pharmaceutical company focused on branded generics across chronic and acute therapy areas. The IPO is a **100% Offer for Sale (OFS)**, meaning the company is not raising fresh capital; existing shareholders are selling part of their stake.
2. Corona Remedies IPO Details
| Detail | Information |
|---|---|
| Price Band (₹ / share) | ₹1,008 – ₹1,062 |
| Total Issue Size | ₹655.37 crore (OFS only — no fresh issue) |
| Face Value | ₹10 per share |
| Lot Size (Market Lot) | 14 shares |
| Issue Type | Book-built, 100% OFS |
| Allocation (Tentative) | QIB: 50% Retail: 35% NII/HNI: 15% |
| IPO Open | 8 December 2025 |
| IPO Close | 10 December 2025 |
| Allotment Date | 11 December 2025 (Tentative) |
| Refunds / Demat Credit | 12 December 2025 (Tentative) |
| Listing Date | 15 December 2025 (Expected) |
| Listing Exchange | BSE & NSE |
3. Company Overview
Founded in 2002, Corona Remedies manufactures and markets branded generic formulations across major therapies including cardiology, diabetology, gastro-intestinal, dermatology, and women's health. The company has a strong domestic market presence and expanding distribution network.
The company filed its **DRHP in May 2025** and **RHP in December 2025** with SEBI.
4. Financial Performance
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | ₹950 crore | ₹1120 crore | ₹1260 crore |
| PAT | ₹98 crore | ₹125 crore | ₹147 crore |
| EBITDA Margin | 17% | 18% | 19% |
| Debt-Equity Ratio | 0.30 | 0.25 | 0.22 |
5. Strengths
- Strong presence in branded generics with defensive demand
- Consistent financial growth and improving profitability
- Low leverage and healthy balance sheet
- Expanding distribution across India
- Stable domestic-focused business model
6. Risks & Challenges
- 100% OFS — no fresh capital infusion
- High competition from large pharma companies
- Regulatory risks in the pharma industry
- Pricing pressure in domestic market
7. Grey Market Premium (GMP) – Trend
| Date | GMP (₹) |
|---|---|
| 4 December 2025 | ₹300 |
| 5 December 2025 | ₹358 |
| 6 December 2025 | ₹362 |
| 8 December 2025 | ₹280 |
Note: GMP is unofficial and market-driven; it does not guarantee listing gains.
8. Subscription Status
Subscription numbers will be updated during the IPO window. Early sentiment indicates strong interest from QIBs and HNIs, followed by retail investors.
9. Corona Remedies IPO Allotment Status
Allotment can be checked online once announced on the registrar’s portal.
🔗 Check Corona Remedies IPO Allotment Status (Link will be updated)
10. Basis of Allotment
Basis of Allotment will be released after the final subscription data. In case of heavy oversubscription, retail allotment may be done through a lottery system.
11. Review & Recommendation
Corona Remedies operates in a stable, evergreen pharma segment with consistent earnings and low debt levels. The company’s strong domestic presence and branded generics portfolio make it a solid long-term candidate.
Short-Term View: Moderate-to-good listing gains possible depending on final GMP and subscription.
Long-Term View: Suitable for investors seeking steady growth in pharma sector.
.jpg)